Doctor Nathalie Gaspar

Dr Nathalie Gaspar is a paediatric oncologist at Gustave Roussy, where she combines clinical and scientific expertise in paediatric and AYA oncology and preclinical drug development, notably acquired at the Institute of Cancer Research (UK).

Since 2009, she has led the Adolescent and Young Adult (AYA) Unit and the SPIAJA programme (Structuring Interdisciplinary Care for Adolescents and Young Adults) at Gustave Roussy, a pioneering initiative aimed at improving care for this specific population. Dr Gaspar plays a leading role both nationally and internationally in AYA care. She is a member of the GO-AJA association and the ESMO-SIOPE AYA Educational Working Group.

She is also involved in early drug development as a member of the Innovative Therapeutics for Children and Adolescents with Cancer (ITCC) consortium. Furthermore, she co-chairs the Fostering Age Inclusive Research (FAIR) working group within the ACCELERATE programme, which aims to promote inclusive research for young adults.

Dr Gaspar’s main research focus is on AYA cancers, with particular attention to bone sarcomas, from basic biology to clinical application. Since 2018, she has been the paediatric lead for the French bone sarcoma group, GROUPOS. Dr Gaspar is the principal investigator (PI) of several national and international therapeutic trials aimed at combating osteosarcoma and Ewing sarcoma, from diagnosis through to relapse.

In parallel, she oversees the BiiOSTeam (U1015) at Gustave Roussy, dedicated to biological and bioinformatics research on osteosarcoma. She also leads the national BoOST-DataS programme, a clinical, biological, genomic, and radiomic database dedicated to osteosarcoma.

She chairs the FOSTER consortium (Fight OsteoSarcoma Through European Research) and is a member of the executive committee of the Euro-Ewing Consortium (EEC). Lastly, she co-chairs HiBisCus, a transatlantic project focused on bone sarcomas within the Pediatric Cancer Data Commons.